Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICTCAR 023 (Innovative Cellular Therapeutics)
- Development stage
- Unknown
- Lead developer
- Innovative Cellular Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Subcutaneous
01
Overview
**ICTCAR 023** is an investigational, genetically engineered CAR-T-cell therapy developed by Innovative Cellular Therapeutics for relapsed or refractory thyroid cancer. It is publicly listed as an alias of dPD-1(TSHR+CD19) CAR-T cells and is designed around CAR recognition of thyroid-stimulating hormone receptor and CD19. A published clinical report describes the related TSHR + CD19 CAR-T product as a combination of two second-generation CAR-T components directed at both antigens; antigen engagement is intended to activate infused T cells and drive cytotoxic elimination of antigen-expressing cells. Publicly available records do not fully disclose the exact molecular design represented by the dPD-1 feature of the product name. ([synapse.zhihuiya.com](https://synapse.zhihuiya.com/drug/9f915a7a4e8946deb2d682ee33f1b407))
- Other names
- dPD-1 (TSHR+CD19) CART cellsdPD-1(TSHR+CD19)
02
Targets
CD19 (B lymphocyte antigen CD19)TSHR (Thyroid-stimulating hormone receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on ICTCAR 023 (Innovative Cellular Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICTCAR 023 (Innovative Cellular Therapeutics).